Why 6 strains?
The beneficial effects of probiotics are both strain- and dose-specific. A combination of various probiotic strains working together has been shown to be the most effective
in the gut6. In addition, more significant results can be achieved with multiple strains in combination compared to single strain preparations7.
Scheduling status: S0. Proprietary name (and dosage form): PROBILIFT ACUTE & DAILY (capsules). Pharmacological classification: D.34.9 Probiotic. Complementary Medicine. Health Supplement. Pharmacological action: Probiotics are beneficial bacteria, essential for improving intestinal health. Certain medication or disease states can affect microflora and therefore increase the risk and susceptibility of gut infections. PROBILIFT is a probiotic supplement specially formulated with 6 probiotic strains. By supplementing your diet with PROBILIFT, you can strengthen your barrier effect to keep you healthy. Probiotics can increase the levels of beneficial bacteria in the gut, creating an environment that is unfavourable to the growth of harmful bacteria. By introducing live probiotic cultures to the intestinal tract, the beneficial gut flora populations are increased and transitory flora, including pathogenic or bad bacteria, are not able to colonise the intestine. Identification: PROBILIFT is opaque white gelatine capsules filled with a white to off-white powder. Presentation PROBILIFT is supplied as 10 & 30 capsules packed in a PVDC/aluminium blister. Agera Health. email@example.com | www.agerahealth.co.za 10 & 30 Capsules.
- Binns, N. (2013) Probiotics, Prebiotics and the Gut Microbiota. ILSI Europe Concise Monograph Series.
- Fooks, L. J., Fuller, R., Gibson, G. R. (1999). Prebiotics, probiotics and human gut microbiology. International Dairy Journal, 9, 53-61.
- Kyne, L., Kelly, C. P. (2001). Recurrent Clostridium difficile diarrhoea. Gut, 49, 152–153.
- Sazawal, S., Hiremath, G., Dhingra, U., Malik, P., Deb, S, Black, R. E. (2006). Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. The Lancet Infectious Diseases, 6(6), 374 –382.
- Guandalini, S. (2006). Probiotics for children: use in diarrhea. Journal of Clinical Gastroenterology, 40(3), 244–248.
- Timmerman, H. M., Koning, C. J., Mulder, L., Rombouts, F. M., Beynen, A. C. (2004). Monostrain, multistrain and multispecies probiotics: a comparison of functionality and efficacy. International Journal of Food Microbiology, 96(3), 219-233.
- Leyer, G. J., Li, S., Mubasher, M. E., Reifer, C., Arthur C. Ouwehand, A. C. (2009). Probiotic Effects on Cold and Influenza-Like Symptom Incidence and Duration in Children. Pediatrics, 124, 172-179.
- Ringel, Y., Ringel-Kulka, T., Maier, D., Carroll, I., Galanko, J. A., Leyer, G., Palsson, O. S. (2011). Clinical trial: Probiotic Bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 Versus Placebo for the Symptoms of Bloating in Patients with Functional Bowel Disorders – a Double-Blind Study. Journal of Clinical Gastroenterology, 45(6), 518–525.
- Van der Kleij, H., O’Mahony, C., Shanahan, F., O’Mahony, L., Bienenstock, J. (2008). Protective effects of Lactobacillus reuteri and Bifidobacterium infantis in murine models for colitis do not involve the vagus nerve. American Journal of Physiology- Regulatory, Integrative & Comparative Physiology, 295, 1131–1137.
- Rautava, S., Kalliomaki, M., Isolauri, E. (2005). New therapeutic strategy for combating the increasing burden of allergic disease: probiotics: a Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI) Research Group report. Journal of Allergy & Clinical Immunology, 116(1), 31–37.
- Biagi, E., Candela, M., Fairweather-Tait, S., (2012). Aging of the human metaorganism: the microbial counterpart. Age, 34, 247–267.